Compare DOYU & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOYU | CNTN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.8M | 146.5M |
| IPO Year | 2019 | 2021 |
| Metric | DOYU | CNTN |
|---|---|---|
| Price | $4.72 | $2.45 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 33.1K | ★ 625.3K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.18 | $1.75 |
| 52 Week High | $7.80 | $5.27 |
| Indicator | DOYU | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 58.47 | 64.33 |
| Support Level | $4.71 | $2.09 |
| Resistance Level | $4.88 | $3.80 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 89.72 | 94.78 |
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company aims to build an integrated game-centric ecosystem of livestreaming, video, voice, graphic content, and other interactive and community features. The company operates the platform both on mobile apps and PC portals, through which users can enjoy immersive and interactive games and entertainment livestreaming, access a wide array of video and graphic content, and participate in community events and discussions.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.